Aripiprazole for treatment-resistant schizophrenia: Results of a multicenter, randomized, double-blind, comparison study versus perphenazine

Journal of Clinical Psychiatry

Volumn 68, Issue 2, 2007, Pages 213-223

  Kane, John M ^a,d   Meltzer, Herbert Y ^b   Carson Jr , William H ^c   McQuade, Robert D ^c   Marcus, Ronald N ^d   Sanchez, Raymond ^d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BENZATROPINE; LORAZEPAM; OLANZAPINE; PERPHENAZINE; RISPERIDONE;

ACCIDENTAL INJURY; ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PSYCHOSIS; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; SYNCOPE; TREATMENT RESPONSE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 33847656202     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0206     Document Type: Article

References (51)

1. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-920
2. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796
3. Bridler R, Umbricht D. Atypical antipsychotics in the treatment of schizophrenia. Swiss Med Wkly 2003;133:63-76
4. Dossenbach M, Arango-Davila C, Silva Ibarra H, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) Study. J Clin Psychiatry 2005;66:1021-1030
5. Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003;64:14-17
6. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004;65:500-508
7. International Psychopharmacology Algorithm Project. Available at: http://www.ipap.org. Accessed April 5, 2006
8. Lindenmayer JP, Czobor P, Volavka J, et al. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. J Clin Psychiatry 2004;65:551-556
9. Meltzer HY. Treatment-resistant schizophrenia: the role of clozapine. Curr Med Res Opin 1997;14:1-20
10. Kane JM, Marder SR, Schooler NR, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001;58:965-972
11. Begum M. Clozapine-induced stuttering, facial tics and myoclonic seizures: a case report [letter]. Aust N Z J Psychiatry 2005;39:202
12. Merrill DB, Ahmari SE, Bradford JM, et al. Myocarditis during clozapine treatment. Am J Psychiatry 2006;163:204-208. Correction 2006;2163:2556
13. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167
14. Hellewell JS. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 1999;60:14-19
15. Small JG, Milstein V, Marhenke JD, et al. Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 1987;48:263-267
16. Bitter I, Dossenbach MR, Brook S, et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:173-180
17. Soholm B, Lublin H. Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients: a mirror study. Acta Psychiatr Scand 2003;107:344-350
18. Conley RR, Tamminga CA, Kelly DL, et al. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry 1999;46:73-77
19. Dossenbach MR, Kratky P, Schneidman M, et al. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry 2001;62:28-34
20. Dossenbach MRK, Beuzen JN, Avnon M, et al. The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine. Clin Ther 2000;22:1021-1034
21. Wahlbeck K, Cheine M, Tuisku K, et al. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:911-922
22. Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 1998;155:499-504
23. Breier AF, Malhotra AK, Su TP, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999;156:294-298
24. Wirshing DA, Marshall BD Jr, Green MF, et al. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999;156:1374-1379
25. Conley RR, Kelly DL, Nelson MW, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol 2005;28:163-168
26. Lindenmayer JP, Volavka J, Lieberman J, et al. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. J Clin Psychopharmacol 2001;21:448-453
27. Kane JM, Rajadhyaksha S, Giller E. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2006;21:21-28
28. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-389
29. Byars A, Burris KD, Jordan S, et al. Aripiprazole, a dopamine-serotonin system stabilizer [abstract]. Eur Neuropsychopharmacol 2002;12:S290
30. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 2002;441:137-140
31. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771
32. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-1056
33. Cutler AJ, Marcus RN, Hardy SA, et al. The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia. CNS Spectr 2006;11:691-702
34. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev 2004;CD004578
35. Kane JM, Leucht S, Carpenter D, et al. Expert Consensus Guideline Series. Optimizing pharmacologic treatment of psychotic disorders: introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64(suppl 12):5-19
36. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
37. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
38. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
39. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
40. Lehman AF, Postrado LT, Rachuba LT. Convergent validation of quality of life assessments for persons with severe mental illnesses. Qual Life Res 1993;2:327-333
41. Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med 1997;337:809-815
42. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;45(suppl 212):11-19
43. Psychopharmacology Research Branch, National Institute of Mental Health. Abnormal Involuntary Movement Scale (ATMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:534-537
44. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676
45. Pantelis C, Lambert TJ. Managing patients with "treatment- resistant" schizophrenia. Med J Aust 2003;178:562-566
46. Robinson DG, Woemer MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-549
47. Kinon BJ, Kane JM, Chakos M, et al. Possible predictors of neuroleptic-resistant schizophrenic relapse: influence of negative symptoms and acute extrapyramidal side effects. Psychopharmacol Bull 1993;29:365-369
48. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999;35:S75-S86
49. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-337
50. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690
51. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136